主要研究方向：疫苗临床研究，现场流行病学
主持/参与项目：国家科技重大专项、国家重点研发计划各1项，承担云南省重点研发计划等科研项目2项。
社会任职：中国疫苗行业协会疫苗临床研究分会副主任委员，中华预防医学会疫苗临床研究专业委员会常委等。
代表论文：1.Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults. Cell Research, Aug 2022.(第一作者，IF: 46.297)；2.Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, 1rmutivima, controlled, phase 3b trial. eClinical Medicine, Sep 2023.(第一作者，IF: 17.033)；3.Comparing recombinant human rabies monoclonal antibody (1rmutivimab)with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: A phase III, randomized, double-blind, non-inferiority trial. The International Journal of Infectious Diseases, Sep 2023.(第一作者，IF: 4.8)；4.Safety, Immunogenicity and Lot-to-Lot Consistency of Sabin-Strain Inactivated Poliovirus Vaccine in 2-Month-Old Infants: A Double-Blind, Randomized Phase III Trial. Vaccines (Basel). (通讯作者，IF: 4.961)。